SCHEMBL5512150

SCHEMBL5512150

O=C(/C=C/c1ccc(O)c(O)c1)c1cc(O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.81
KMT2A Q03164 3/20 0.79
MEN1 O00255 2/20 0.79
EGFR P00533 1/20 0.79
SRC P12931 1/20 0.79
AKR1B1 P15121 1/20 0.79
NFKB1 P19838 1/20 0.79
CDK2 P24941 1/20 0.79
HSD17B2 P37059 1/20 0.79
PIK3CA P42336 1/20 0.79
NFKB2 Q00653 1/20 0.79
RELA Q04206 1/20 0.79
HDAC6 Q9UBN7 1/20 0.79
GUSB P08236 4/20 0.73
MAPT P10636 3/20 0.71
KDM4E B2RXH2 2/20 0.71
MAPK1 P28482 2/20 0.71
GAA P10253 1/20 0.71
PTGS1 P23219 1/20 0.71
PTGS2 P35354 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969800 1.00 CHRNA7 (0.81) CHRNA7KMT2AMEN1EGFRSRC
SCHEMBL634059 0.90 CHRNA7 (1.00) CHRNA7KMT2AMEN1EGFRSRC
SCHEMBL634060 0.90 CHRNA7 (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL30383523 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL243647 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL25202104 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL29724857 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL139243 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL243646 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC
Butein SCHEMBL505501 0.89 KMT2A (1.00) CHRNA7KMT2AMEN1EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP claimed
CN-119409588-A Caffeoyl amino acid methyl ester derivative and preparation method and application thereof 西北大学 2025-02-11 CN disclosed
US-7268160-B2 Remedies TAKARA BIO, INC. (JP) 2007-09-11 US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US disclosed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP CHRNA7 4487/4885KMT2A 4418/4885MEN1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.